Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts

An evidence-based consensus meeting was held with urologists, a pharmacist and a cardiologist to perform a structured benefit-risk analysis of reclassifying tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor for treatment of erectile dysfunction (ED), to be available without prescription in Germ...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Kurt, May, Uwe, Beecken, Wolf-Dietrich, Hatzichristodoulou, Georgios, Böhm, Michael, Fink, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590875/
https://www.ncbi.nlm.nih.gov/pubmed/37876727
http://dx.doi.org/10.3389/fphar.2023.1254706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590875/
https://www.ncbi.nlm.nih.gov/pubmed/37876727
http://dx.doi.org/10.3389/fphar.2023.1254706

Ejemplares similares